Vildagliptin Versus Liraglutide - Patient Preference After Receiving Both Medications (PREFER)
A Randomized, Open-label, Cross-over Study to Evaluate Patient Preferences for Eucreas® Versus Victoza® as add-on to Metformin in Type 2 Diabetes Mellitus Patients Who Did Not Have Adequate Glycaemic Control With Metformin.
Sponsor: Novartis Pharmaceuticals
Listed as NCT01518101, this PHASE4 trial focuses on Type 2 Diabetes and remains completed. Sponsored by Novartis Pharmaceuticals, it has been updated 6 times since 2012, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE4
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE4
-
Mar 2017 — Jun 2018 [monthly]
Completed PHASE4
▶ Show 1 earlier version
-
Jan 2017 — Mar 2017 [monthly]
Completed PHASE4
First recorded
Jan 2012
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Novartis Pharmaceuticals
For direct contact, visit the study record on ClinicalTrials.gov .